Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2017
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2017
SUMMARY
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Non-Hodgkin Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atherosclerosis, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Follicular Lymphoma, Head And Neck Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leukemias, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and T-Cell Lymphomas.
Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Non-Hodgkin Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atherosclerosis, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Follicular Lymphoma, Head And Neck Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leukemias, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and T-Cell Lymphomas.
Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
- The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
NovImmune SA
PharmAbcine Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-6H12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD47 and PDL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit CD47 for Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hu-5F9G4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSTx-23 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRF-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ti-061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting
Dec 06, 2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Nov 13, 2017: Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Nov 13, 2017: Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)
Nov 10, 2017: Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Oct 05, 2017: Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade
May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting
Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients
Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update
Mar 31, 2017: Aurigene to Present Data on CD47-SIRP? interaction program at the AACR 2017
Mar 15, 2017: Patents Licensed to Synthon Relating to the CD47-SIRPa Pathway Resist Challenges in the U.S. and Europe
Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621
Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
NovImmune SA
PharmAbcine Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
ALX-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-6H12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD47 and PDL1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit CD47 for Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hu-5F9G4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-2504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSTx-23 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD47 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRF-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ti-061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting
Dec 06, 2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Nov 13, 2017: Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Nov 13, 2017: Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)
Nov 10, 2017: Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Oct 05, 2017: Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade
May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting
Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients
Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update
Mar 31, 2017: Aurigene to Present Data on CD47-SIRP? interaction program at the AACR 2017
Mar 15, 2017: Patents Licensed to Synthon Relating to the CD47-SIRPa Pathway Resist Challenges in the U.S. and Europe
Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621
Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Pipeline by Celgene Corp, H2 2017
Pipeline by Forty Seven Inc, H2 2017
Pipeline by GigaGen Inc, H2 2017
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
Pipeline by NovImmune SA, H2 2017
Pipeline by PharmAbcine Inc, H2 2017
Pipeline by Surface Oncology Inc, H2 2017
Pipeline by Synthon Holdings BV, H2 2017
Pipeline by Trillium Therapeutics Inc, H2 2017
Dormant Projects, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Pipeline by Celgene Corp, H2 2017
Pipeline by Forty Seven Inc, H2 2017
Pipeline by GigaGen Inc, H2 2017
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
Pipeline by NovImmune SA, H2 2017
Pipeline by PharmAbcine Inc, H2 2017
Pipeline by Surface Oncology Inc, H2 2017
Pipeline by Synthon Holdings BV, H2 2017
Pipeline by Trillium Therapeutics Inc, H2 2017
Dormant Projects, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
NovImmune SA
PharmAbcine Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Aurigene Discovery Technologies Ltd
Celgene Corp
Forty Seven Inc
GigaGen Inc
Hummingbird Bioscience Pte Ltd
NovImmune SA
PharmAbcine Inc
Surface Oncology Inc
Synthon Holdings BV
Trillium Therapeutics Inc
